证券代码：002099 证券简称：海翔药业 公告编号：2025-009 浙江海翔药业股份有限公司 第七届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）第七届监事会第八次会议 于 2025 年 4 月 18 日以电子邮件形式发出通知，于 2025 年 4 月 28 日以现场方 式在公司会议室召开，会议应出席监事 3 人，实际出席监事 3 人，公司董事、高 级管理人员列席会议。会议召开符合《公司法》及《公司章程》的规定，合法有 效。会议由监事会主席陈敏杰先生主持，经过与会监事的充分讨论，会议审议通 过了如下议案： 一、审议通过了《2024 年度监事会工作报告》 表决结果：同意 3 票，反对 0 票，弃权 0 票 内容详见巨潮资讯网《2024 年度监事会工作报告》。 本议案需提交公司股东大会审议。 二、审议通过了《2024 年度财务决算报告》 公司 2024 年度财务报告已经天健会计师事务所（特殊普通合伙）审计，并 出具了标准无保留意见的审计报告。经审计，公司 2024 年度实现营业收入 1,9 ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,938,465,657.86, a decrease of 10.75% compared to CNY 2,171,886,869.45 in 2023[25]. - The net profit attributable to shareholders for 2024 was CNY -330,267,195.37, showing an improvement of 21.38% from CNY -420,055,857.71 in 2023[25]. - The net cash flow from operating activities decreased by 27.31% to CNY 174,834,870.57 in 2024, down from CNY 240,536,591.52 in 2023[25]. - The basic earnings per share for 2024 was CNY -0.21, an improvement of 19.23% from CNY -0.26 in 2023[25]. - Total assets at the end of 2024 were CNY 7,456,044,106.37, a decrease of 0.85% from CNY 7,520,092,953.12 at the end of 2023[25]. - The net assets attributable to shareholders decreased by 8.33% to CNY 5,139,071,751.73 at the end of 2024, down from CNY 5,606,352,298.36 at the end of 2023[25]. - The company's revenue after deducting certain amounts was CNY 1,922,031,621.40 in 2024, compared to CNY 2,162,748,448.50 in 2023[26]. - The company reported a weighted average return on equity of -6.19% for 2024, an improvement from -7.18% in 2023[25]. - In 2024, the company achieved revenue of 1.938 billion yuan, a year-on-year decrease of 10.75%[64]. - The net profit attributable to shareholders was -330 million yuan, an increase of 21.38% year-on-year, while the net profit after deducting non-recurring gains and losses was -340 million yuan, a slight increase of 0.11%[64]. Corporate Governance - The board of directors and management confirm the accuracy and completeness of the financial report[4]. - The company adheres to strict information disclosure practices, ensuring all investors have equal access to information[128]. - The company has established a value management system and disclosed a valuation enhancement plan[124]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, organization, and business operations[129]. - The company has a complete and independent business structure, with no competition with its controlling shareholder[130]. - The board of directors includes four specialized committees to provide scientific and professional advice for decision-making[127]. - The company has implemented a performance assessment mechanism linking senior management remuneration to company performance[144]. - The board approved the annual financial report and profit distribution plan for 2023[146]. - The company has established a comprehensive quality management system in accordance with cGMP standards, with multiple production sites passing inspections from various international regulatory bodies[58]. Market Position and Strategy - The company is a key supplier in the global penem industry, with a comprehensive product line including meropenem and imipenem, and has established a competitive advantage in the high-end market[38]. - The company has established partnerships with global pharmaceutical giants like Pfizer and Meiji, enhancing its position in the CMO/CDMO business[41]. - The pharmaceutical industry is expected to see a growth in demand due to the optimization of centralized procurement policies, with a forecasted increase in hospital treatment needs[44]. - The market for chemical raw materials is projected to exceed ¥680 billion by 2028, indicating a robust growth trajectory for the industry[45]. - The company is actively developing a pipeline of new products, including ophthalmic medications and cardiovascular drugs, to capture emerging market opportunities[38]. - The company aims to enhance its competitive strength by advancing its integrated strategy of intermediates, active pharmaceutical ingredients, and formulations, while expanding its global market presence[118]. - The company is focused on developing new technologies and products to drive future growth[135]. - The company plans to expand its market presence and enhance its product offerings in the upcoming fiscal year[135]. Research and Development - The company has developed 16 patents and achieved international advanced levels in product technology, particularly in the production of reactive dyes[53]. - The company is investing in research and development, with over 20 major scientific projects funded by national grants[141]. - Research and development expenses increased by 12.01% to ¥129,445,758.14 in 2024 from ¥115,564,760.64 in 2023[89]. - The company has 353 R&D personnel in 2024, representing a 3.22% increase from 342 in 2023[90]. - The company has developed innovative drugs that have entered clinical phases I and II, with over 40 patents granted in the US, Europe, and China[137]. Environmental and Social Responsibility - The company has implemented strict compliance with environmental protection laws and industry standards in its operations[171]. - The company has a comprehensive emergency response plan for environmental incidents, ensuring timely and effective management of such events[177]. - The company has invested in improving environmental protection infrastructure, leading to better control of pollutant emissions[178]. - The company has a dedicated team for daily environmental monitoring and analysis, ensuring stable operation of pollution control facilities[178]. - The company has committed to paying environmental protection taxes in accordance with relevant laws and regulations[178]. - The company actively recruited 12 workers from economically challenged areas, contributing to rural revitalization efforts[181]. Financial Management - The company has engaged Tianjian Accounting Firm for auditing services[25]. - The company has implemented various employee incentive programs, including stock option plans and employee shareholding plans, to enhance team motivation and collaboration[63]. - The company has received environmental impact assessment approvals for several projects, indicating ongoing compliance with regulatory requirements[55]. - The company has established a derivative investment management system to control trading risks and ensure compliance with internal procedures[104]. - The company has taken measures to avoid or minimize related party transactions with its subsidiaries[184]. Operational Challenges - The company has experienced significant personnel turnover in key technical positions, leading to concerns about outdated core technologies[167]. - The company has reported a backlog of inventory and inefficiencies in the use of long-term assets, indicating potential operational challenges[167]. - The company faces risks from international trade dynamics, including protectionism and regulatory changes that may impact drug registration and exports[120]. - The company is monitoring exchange rate fluctuations, particularly the impact of USD settlements on profitability, and is implementing risk management strategies[121]. Shareholder Engagement - The company held a conference call on April 29, 2024, to discuss its operational performance with institutional investors[123]. - The company reported a 41.41% participation rate in the annual general meeting held on May 20, 2024[131]. - The first extraordinary general meeting of 2024 had a participation rate of 41.95% and was held on November 15, 2024[131]. - The company has conducted various investor communication activities to discuss its operational status[123]. Compliance and Internal Control - The internal control system is deemed effective and complies with national laws and regulations, ensuring good control and prevention in various operational processes[163]. - The company has not reported any major defects in its internal control system during the reporting period[164]. - The company has not disclosed any major defects in its financial reporting, with zero instances reported[168]. - The company has not identified any significant deficiencies in non-financial reporting controls[168].

Financial Performance - The company's revenue for Q1 2025 was ¥486,432,558.84, a decrease of 7.95% compared to ¥528,463,890.64 in the same period last year[5]. - Net profit attributable to shareholders was ¥9,229,942.41, down 71.68% from ¥32,593,338.56 year-on-year[5]. - Basic earnings per share decreased by 50.00% to ¥0.01 from ¥0.02 in the same period last year[5]. - Net profit for the period was ¥8,313,435.12, down from ¥32,097,804.14, indicating a significant decrease of approximately 74.1% year-over-year[19]. - The total comprehensive income for the period was ¥8,313,435.12, down from ¥32,097,804.14, indicating a decrease of approximately 74.1% year-over-year[20]. - Cash received from sales of goods and services was ¥344,510,881.75, down from ¥363,343,382.36, a decrease of about 5.5% year-over-year[21]. Cash Flow - The net cash flow from operating activities was negative at -¥24,869,922.89, a decline of 187.30% compared to ¥28,489,229.96 in the previous year[5]. - Operating cash inflow totaled $415.84 million, a decrease from $440.57 million in the previous period[22]. - Net cash outflow from operating activities was $24.87 million, compared to a net inflow of $28.49 million previously[22]. - Investment activities generated a net cash inflow of $348.30 million, a significant improvement from a net outflow of $58.75 million last period[22]. - The net increase in cash and cash equivalents was $616.17 million, up from $210.10 million in the prior period[22]. - The ending balance of cash and cash equivalents was $1.55 billion, compared to $1.46 billion at the end of the previous period[22]. Assets and Liabilities - Total assets increased by 1.84% to ¥7,592,942,196.41 from ¥7,456,044,106.37 at the end of the previous year[5]. - Total current assets increased to ¥3,123,540,366.39 from ¥2,890,751,484.57, reflecting a growth of approximately 8.06%[15]. - Total liabilities increased to ¥2,452,798,237.92 from ¥2,324,213,583.00, marking an increase of about 5.5% year-over-year[16]. - Total equity attributable to shareholders increased slightly to ¥5,148,301,694.14 from ¥5,139,071,751.73, reflecting a marginal increase of approximately 0.2% year-over-year[16]. Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 31,964[11]. - Zhejiang Donggang Industrial Co., Ltd. holds 32.37% of shares, totaling 523,982,587 shares, making it the largest shareholder[11]. - The largest shareholder, Wang Yunfu, holds 7.34% of shares, totaling 118,800,000 shares[11]. - The company has repurchased 31,478,531 shares, accounting for 1.94% of the total share capital as of March 31, 2025[12]. Operating Costs and Expenses - Total operating costs increased to ¥466,678,445.96 from ¥452,546,121.15, reflecting an increase of about 3.0% year-over-year[18]. - The company experienced a 41.71% increase in taxes and surcharges, amounting to ¥8,884,372.07 compared to ¥6,269,407.94 in the previous year[9]. - The company reported a 1992.86% increase in other operating expenses, totaling ¥4,103,343.90, primarily due to tax penalties[9]. - Cash paid to employees increased to $94.77 million from $70.85 million, reflecting a rise of approximately 33.8%[22]. - Cash paid for taxes rose to $33.11 million, compared to $27.43 million, marking a 20.6% increase[22]. Investment Income - The company reported a significant increase in investment income, rising by 130.64% to ¥1,846,487.16 from a loss of ¥6,025,573.27 in the previous year[9]. - The net cash flow from investing activities improved significantly, reaching ¥348,300,280.99 compared to -¥58,747,912.25 in the same period last year, an increase of 692.87%[9]. - Cash inflow from other investment activities surged to $388.22 million from $4.62 million, indicating a substantial growth[22]. Research and Development - Research and development expenses remained stable at ¥30,648,501.47 compared to ¥30,007,076.80, showing a slight increase of approximately 2.1% year-over-year[19]. - The company has not disclosed any new product or technology developments in the current reporting period[13].

证券代码：002099 证券简称：海翔药业 公告编号：2025-008 浙江海翔药业股份有限公司 第七届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）第七届董事会第十四次 会议于 2025 年 4 月 18 日以电子邮件形式发出通知，于 2025 年 4 月 28 日以现 场方式在公司会议室召开，会议应出席董事 7 人，实际出席董事 7 人，公司监 事、高级管理人员列席会议。会议召开符合《公司法》及《公司章程》的规 定，合法有效。会议由董事长王扬超先生主持，经过与会董事的充分讨论，会 议审议通过了如下议案： 一、审议通过了《2024 年度董事会工作报告》 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票。 公司独立董事向董事会递交了关于独立性的自查报告和 2024 年度述职报 告，并将在公司 2024 年年度股东大会上述职。 内容详见巨潮资讯网《2024 年度董事会工作报告》《董事会对独立董事独 立性评估的专项意见》《2024 年度独立董事述职报告》。 二、审议通过了《2024 ...

证券代码：002099 证券简称：海翔药业 公告编号：2025-011 浙江海翔药业股份有限公司 关于2024年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、审议程序 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开 第七届董事会第十四次会议、第七届监事会第八次会议，审议通过了《2024 年度 利润分配预案》，公司 2024 年度利润分配预案为：不派发现金红利，不送红股， 不以公积金转增股本。该议案尚需提交公司 2024 年度股东大会审议。 二、2024 年度利润分配的基本情况 经天健会计师事务所（特殊普通合伙）审计，公司 2024 年度归属于上市公 司股东的净利润为-330,267,195.37 元，母公司实现净利润 110,257,859.37 元。 根据《公司法》《公司章程》的有关规定，按照 2024 年度母公司实现的净利润 提取 10%的法定盈余公积金 11,025,785.94 元。截至 2024 年 12 月 31 日止，公 司可供分配利润为 475,206,929.21 元(合并报表数 ...

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 海翔药业公司管理层的责任是提供真实、合法、完整的相关资料，按照《上 市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会 公告〔2022〕26 号）和《深圳证券交易所上市公司自律监管指南第 1 号——业 务办理（2024 年修订）》（深证上〔2024〕397 号）的规定编制汇总表，并保证 其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 二、非经营性资金占用及其他关联资金往来情况汇总表……………第 3 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2025〕8304 号 浙江海翔药业股份有限公司全体股东： 我们接受委托，审计了浙江海翔药业股份有限公司（以下简称海翔药业公司） 2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权 益变动表，以及财务报表附注，并出具了审计报告。在此基础上，我们审计了后 附的海翔药业公司 ...

国泰海通证券股份有限公司 关于浙江海翔药业股份有限公司 一、募集资金基本情况 经中国证券监督管理委员会证监许可〔2016〕765 号文核准，并经深圳证券 交易所同意，海翔药业由主承销商国泰海通证券股份有限公司采用非公开发行方 式，向特定对象非公开发行人民币普通股(A 股)股票 99,890,023 股，发行价为每 股人民币 10.28 元，共计募集资金 1,026,869,436.44 元，坐扣承销费和保荐费等 10,000,000.00 元(含税)后的募集资金为 1,016,869,436.44 元，已由主承销商国泰 海通证券股份有限公司于 2016 年 9 月 1 日汇入公司募集资金监管账户。扣除承 销费及保荐费、律师费、会计师费用、登记费等发行费用 12,465,829.73 元后， 公司本次募集资金净额 1,014,403,606.71 元。上述募集资金到位情况业经天健会 计师事务所(特殊普通合伙)验证，并由其出具《验资报告》(天健验〔2016〕358 号)。公司根据法律、法规和规范性文件的规定对募集资金采取了专户存储管理。 二、募集资金使用情况 截至 2024 年 12 月 31 日，公司募集资金使 ...

国泰海通证券股份有限公司 关于浙江海翔药业股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 浙江海翔药业股份有限公司（以下简称"海翔药业"或"公司"）的持续督导机 构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上 市公司募集资金管理和使用的监管要求》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，对海翔 药业 2024 年度募集资金存放与使用情况进行了审慎核查，具体情况如下： 一、保荐机构核查工作 （一）募集资金管理情况 为了规范募集资金的管理和使用，提高资金使用效率和效益，保护投资者权 益，海翔药业按照《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修 订）》（证监会公告〔2022〕15 号）和《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作（2023 年 12 ...

目 录 一、关于营业收入扣除情况的专项核查意见………………………第 1—2 页 二、2024 年度营业收入扣除情况表…………………………………第 3—5 页 关于营业收入扣除情况的专项核查意见 天健审〔2025〕8305 号 浙江海翔药业股份有限公司全体股东： 我们接受委托，审计了浙江海翔药业股份有限公司（以下简称海翔药业公司） 2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权 益变动表，以及财务报表附注，并出具了审计报告。在此基础上，我们核查了后 附的海翔药业公司管理层编制的《2024 年度营业收入扣除情况表》（以下简称 扣除情况表）。 一、对报告使用者和使用目的的限定 本报告仅供海翔药业公司年度报告披露时使用，不得用作任何其他目的。我 们同意将本报告作为海翔药业公司年度报告的必备文件，随同其他文件一起报送 并对外披露。 为了更好地理解海翔药业公司 2024 年度营业收入扣除情况，扣除情况表应 当与已审的财务报表一并阅读。 二、管理层的责任 海翔药业公司管理层的责任是提供真实、合法、完整的 ...

目 录 | | | | 二、财务报表 ………………………………………………………第 | 7—14 | 页 | | --- | --- | --- | | （一）合并资产负债表 ……………………………………………第 | | 7 页 | | （二）母公司资产负债表 …………………………………………第 | | 8 页 | | （三）合并利润表 …………………………………………………第 | | 9 页 | | （四）母公司利润表………………………………………………第 | 10 | 页 | | （五）合并现金流量表……………………………………………第 | 11 | 页 | | （六）母公司现金流量表…………………………………………第 | 12 | 页 | | （七）合并所有者权益变动表……………………………………第 | 13 | 页 | | （八）母公司所有者权益变动表…………………………………第 | 14 | 页 | | | | 审 计 报 告 天健审〔2025〕8301 号 浙江海翔药业股份有限公司全体股东： 一、审计意见 我们审计了浙江海翔药业股份有限公司（以下简称海翔药业公司）财务报表， 包括 2024 年 1 ...